Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Change in Cash (2016 - 2025)

Coherus Oncology (CHRS) has disclosed Change in Cash for 13 consecutive years, with -$14.5 million as the latest value for Q4 2025.

  • Quarterly Change in Cash fell 151.15% to -$14.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$37.1 million through Dec 2025, down 262.09% year-over-year, with the annual reading at -$37.1 million for FY2025, 262.09% down from the prior year.
  • Change in Cash hit -$14.5 million in Q4 2025 for Coherus Oncology, up from -$113.6 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $156.9 million in Q1 2024 to a low of -$281.7 million in Q1 2021.
  • Historically, Change in Cash has averaged -$22.6 million across 5 years, with a median of -$3.6 million in 2023.
  • Biggest five-year swings in Change in Cash: tumbled 1884.52% in 2021 and later soared 430.96% in 2024.
  • Year by year, Change in Cash stood at $56.7 million in 2021, then plummeted by 494.07% to -$223.3 million in 2022, then soared by 110.14% to $22.6 million in 2023, then grew by 25.03% to $28.3 million in 2024, then plummeted by 151.15% to -$14.5 million in 2025.
  • Business Quant data shows Change in Cash for CHRS at -$14.5 million in Q4 2025, -$113.6 million in Q3 2025, and $134.5 million in Q2 2025.